On December 19, 2025, Needham downgraded the stock grade of Amicus Therapeutics (NASDAQ:FOLD) from Buy to Hold, with the stock priced at $14.21. Amicus Therapeutics is a biotechnology company known for developing therapies for rare diseases. The downgrade comes amid significant developments in the biotech sector, including BioMarin Pharmaceutical's acquisition of Amicus.
BioMarin Pharmaceutical's acquisition of Amicus Therapeutics is valued at $4.8 billion. This strategic move is set to enhance BioMarin's portfolio by adding two rare disease drugs from Amicus. The acquisition reflects a broader trend of consolidation in the biotech industry, as companies aim to expand their capabilities and product offerings.
Despite the downgrade, FOLD's stock price has seen a notable increase. Currently priced at $14.20, the stock has risen by 30.43%, with a change of $3.31. This increase highlights investor interest, possibly driven by the acquisition news. The stock has fluctuated between $14.16 and $14.36 today, marking its highest price over the past year.
FOLD's market capitalization stands at approximately $4.38 billion, with a trading volume of about 132.8 million shares. The stock's lowest price in the past year was $5.51, indicating significant growth. The acquisition by BioMarin is expected to further influence FOLD's market performance as the deal progresses.
The acquisition of Amicus by BioMarin is a significant development in the biotechnology sector. It underscores the ongoing trend of consolidation, as highlighted by the $4.8 billion all-cash transaction. This move is expected to strengthen BioMarin's market position and drive future growth, benefiting both companies involved.
